Constellation Brands, Inc. · STZ · FY2027 Q1 · Calendar Q2 2026
Constellation Brands Beats on Q1 FY27 Beer Strength, Holds Guidance Amid Macro Uncertainty
Constellation Brands delivered a Q1 FY27 beat driven by beer shipment strength and cost discipline, but the market focused on management's refusal to raise guidance despite favorable Q2/Q3 comparisons. The company faces a tension between strong brand fundamentals and near-term margin pressure from elevated marketing spend (over 10% of net sales in Q2/Q3) and SG&A headwinds tied to the Veracruz brewery ramp. With the stock trading at $130.38 versus a consensus target of $165.20, the market is pricing in meaningful uncertainty around consumer health, particularly within the Hispanic demographic that anchors STZ's core customer base.
Company context
Snapshot as of publicationConstellation Brands, Inc., together with its subsidiaries, produces, imports, markets, and sells beer, wine, and spirits in the United States, Canada, Mexico, New Zealand, and Italy. The company offers beer under the Corona Extra, Corona Familiar, Corona Hard Seltzer, Corona Light, Corona Non-Alcoholic, Corona Premier, Corona Refresca, Modelo Especial, Modelo Chelada, Modelo Negra, Modelo Oro, Victoria, Vicky Chamoy, and Pacifico brands. It also offers wine under the Cook’s California Champagne, Kim Crawford, Meiomi, Mount Veeder, Ruffino, SIMI, My Favorite Neighbor, Robert Mondavi Winery, Schrader, and The Prisoner Wine Company brands; and spirits under the Casa Noble, Copper & Kings, High West, Mi CAMPO, Nelson’s Green Brier, and SVEDKA brands. The company provides its products to wholesale distributors, retailers, on-premise locations, and state alcohol beverage control agencies. Constellation Brands, Inc. was founded in 1945 and is based in Rochester, New York.
Earnings scorecard
Reported versus consensusEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 31, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Barclays | Equal Weight | Equal Weight | Maintain | Jul 21, 2026 |
| Roth Capital | Buy | Buy | Maintain | Jul 2, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Jul 2, 2026 |
| Needham | Buy | Buy | Maintain | Jul 2, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Jul 2, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Jul 2, 2026 |
| Deutsche Bank | Hold | Hold | Maintain | Jul 2, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | Jul 2, 2026 |
| B of A Securities | Underperform | Underperform | Maintain | Jul 2, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Jul 1, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Jun 29, 2026 |
| Jefferies | Hold | Hold | Maintain | Jun 24, 2026 |
| UBS | Buy | Buy | Maintain | Jun 17, 2026 |
| TD Cowen | Buy | Hold | Upgrade | Apr 13, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Apr 10, 2026 |
| Citigroup | Buy | Neutral | Upgrade | Mar 18, 2026 |
| Bernstein | Outperform | Outperform | Maintain | Jan 9, 2026 |
| Goldman Sachs | Buy | Buy | Maintain | Oct 2, 2025 |
| Roth MKM | Buy | Buy | Maintain | Apr 3, 2025 |
| Truist Securities | Hold | Hold | Maintain | Jan 14, 2025 |
| Argus Research | Buy | Hold | Upgrade | Apr 15, 2024 |
| HSBC | Buy | Buy | Maintain | Apr 12, 2024 |
| Wedbush | Outperform | Outperform | Maintain | Apr 10, 2024 |
| Credit Suisse | Outperform | Outperform | Maintain | Jan 6, 2023 |
| Cowen & Co. | Market Perform | Outperform | Downgrade | Jan 6, 2023 |
| Redburn Partners | Buy | Buy | Maintain | Jul 13, 2022 |
| MKM Partners | Neutral | Neutral | Maintain | Jul 1, 2021 |
| OTR Global | Mixed | Positive | Downgrade | Jun 18, 2021 |
| Wolfe Research | Outperform | Outperform | Maintain | Apr 13, 2021 |
| Atlantic Equities | Neutral | Overweight | Downgrade | Oct 14, 2020 |
| Guggenheim | Neutral | Neutral | Maintain | Jun 25, 2020 |
| CFRA | Hold | Hold | Maintain | Apr 3, 2020 |
| SunTrust Robinson Humphrey | Hold | Hold | Maintain | Jul 1, 2019 |
| Susquehanna | Neutral | Negative | Upgrade | Jan 7, 2019 |
| Macquarie | Neutral | Neutral | Maintain | Dec 17, 2018 |
| Bank of America | Buy | Buy | Maintain | Oct 5, 2018 |
| Stifel Nicolaus | Hold | Hold | Maintain | Jul 2, 2018 |
| Stifel | Hold | Hold | Maintain | Jul 2, 2018 |
| Nomura | Neutral | Neutral | Maintain | Sep 17, 2015 |
| CLSA | Outperform | Outperform | Maintain | Sep 1, 2015 |
| Societe Generale | Hold | Sell | Upgrade | Jan 13, 2015 |
| Pivotal Research | Buy | Buy | Maintain | Oct 20, 2014 |
| DA Davidson | Buy | Buy | Maintain | Jan 8, 2014 |
| ISI Group | Strong Buy | Buy | Upgrade | May 16, 2013 |
| Buckingham Research | Buy | Buy | Maintain | Jan 16, 2013 |
| Bank oferica | Buy | Buy | Maintain | Mar 22, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $130.38. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Barclays | Analyst unavailable | $132 | $134.36 | +1.2% | Jul 21, 2026 |
| Deutsche Bank | Steve Powers | $150 | $138.34 | +15.0% | Jul 2, 2026 |
| Morgan Stanley | Dara Mohsenian | $158 | $136.88 | +21.2% | Jul 2, 2026 |
| Barclays | Analyst unavailable | $139 | $136.88 | +6.6% | Jul 2, 2026 |
| Jefferies | Analyst unavailable | $147 | $136.88 | +12.7% | Jul 2, 2026 |
| BMO Capital | Analyst unavailable | $174 | $137.49 | +33.5% | Jul 1, 2026 |
| Jefferies | Analyst unavailable | $157 | $143.36 | +20.4% | Jun 23, 2026 |
| Evercore ISI | Analyst unavailable | $175 | $167.96 | +34.2% | Apr 10, 2026 |
| Barclays | Analyst unavailable | $170 | $167.96 | +30.4% | Apr 10, 2026 |
| Deutsche Bank | Analyst unavailable | $155 | $167.96 | +18.9% | Apr 10, 2026 |
| Needham | Gerald Pascarelli | $185 | $167.96 | +41.9% | Apr 10, 2026 |
| UBS | Analyst unavailable | $186 | $167.96 | +42.7% | Apr 10, 2026 |
| Piper Sandler | Analyst unavailable | $160 | $167.96 | +22.7% | Apr 10, 2026 |
| Wells Fargo | Chris Carey | $185 | $167.96 | +41.9% | Apr 10, 2026 |
| Barclays | Analyst unavailable | $148 | $147 | +13.5% | Jan 12, 2026 |
| BMO Capital | Andrew Strelzik | $190 | $147.51 | +45.7% | Jan 9, 2026 |
| UBS | Peter Grom | $168 | $147.89 | +28.9% | Jan 9, 2026 |
| Bernstein | Analyst unavailable | $197 | $147.96 | +51.1% | Jan 9, 2026 |
| Wells Fargo | Analyst unavailable | $165 | $140.49 | +26.6% | Jan 8, 2026 |
| Wells Fargo | Bonnie Herzog | $160 | $141.17 | +22.7% | Jan 5, 2026 |
| Jefferies | Analyst unavailable | $154 | $142.59 | +18.1% | Dec 16, 2025 |
| Deutsche Bank | Analyst unavailable | $160 | $142.02 | +22.7% | Dec 15, 2025 |
| Piper Sandler | Michael Lavery | $135 | $130.45 | +3.5% | Nov 21, 2025 |
| Barclays | Analyst unavailable | $147 | $142.76 | +12.7% | Oct 9, 2025 |
| Needham | Gerald Pascarelli | $180 | $140.14 | +38.1% | Oct 8, 2025 |
| UBS | Analyst unavailable | $160 | $138.71 | +22.7% | Oct 7, 2025 |
| UBS | Analyst unavailable | $175 | $140.51 | +34.2% | Oct 3, 2025 |
| Bernstein | Analyst unavailable | $195 | $145.88 | +49.6% | Sep 4, 2025 |
| Roth Capital | William Kirk | $209 | $147.28 | +60.3% | Sep 3, 2025 |
| Wells Fargo | Chris Carey | $170 | $146.49 | +30.4% | Sep 3, 2025 |
| Goldman Sachs | Analyst unavailable | $196 | $151.26 | +50.3% | Sep 2, 2025 |
| Goldman Sachs | Boonie Herzog | $225 | $161.32 | +72.6% | Jun 27, 2025 |
| Barclays | Lauren Lieberman | $202 | $161.53 | +54.9% | Jun 26, 2025 |
| UBS | Peter Grom | $195 | $161.53 | +49.6% | Jun 25, 2025 |
| Truist Financial | Bill Chappell | $215 | $187.07 | +64.9% | May 7, 2025 |
| Barclays | Analyst unavailable | $205 | $181.59 | +57.2% | Mar 13, 2025 |
| RBC Capital | Analyst unavailable | $289 | $186.25 | +121.7% | Mar 7, 2025 |
| Morgan Stanley | Dara Mohsenian | $202 | $178.35 | +54.9% | Feb 27, 2025 |
| BMO Capital | Andrew Strelzik | $305 | $245.71 | +133.9% | Oct 15, 2024 |
| Barclays | Lauren Lieberman | $300 | $246.67 | +130.1% | Oct 4, 2024 |
| HSBC | Sorabh Daga | $285 | $246.67 | +118.6% | Oct 4, 2024 |
| Roth Capital | William Kirk | $298 | $246.36 | +128.6% | Oct 4, 2024 |
| Evercore ISI | Robert Ottenstein | $300 | $246 | +130.1% | Oct 4, 2024 |
| Truist Financial | Bill Chappell | $255 | $243.65 | +95.6% | Oct 4, 2024 |
| Jefferies | Kaumil Gajrawala | $309 | $246.67 | +137.0% | Oct 4, 2024 |
| J.P. Morgan | Andrea Teixeira | $307 | $255.67 | +135.5% | Oct 3, 2024 |
| Deutsche Bank | Steve Powers | $256 | $246.78 | +96.3% | Sep 3, 2024 |
| Citigroup | Filippo Falorni | $305 | $246.78 | +133.9% | Sep 3, 2024 |
| Morgan Stanley | Dara Mohsenian | $280 | $244.5 | +114.8% | Aug 26, 2024 |
| Barclays | Lauren Lieberman | $295 | $248.26 | +126.3% | Jul 19, 2024 |
| Wells Fargo | Bonnie Herzog | $300 | $259.14 | +130.1% | Jul 5, 2024 |
| CFRA | Garrett Nelson | $335 | $250.37 | +156.9% | Jul 3, 2024 |
| Barclays | Lauren Lieberman | $288 | $245.49 | +120.9% | May 28, 2024 |
| Jefferies | Kaumil Gajrawala | $311 | $258.77 | +138.5% | May 14, 2024 |
| Argus Research | John Staszak | $306 | $262.24 | +134.7% | Apr 15, 2024 |
| Truist Financial | Bill Chappell | $265 | $262.24 | +103.3% | Apr 15, 2024 |
| RBC Capital | Nik Modi | $308 | $268.34 | +136.2% | Apr 12, 2024 |
| Jefferies | Kaumil Gajrawala | $314 | $268.34 | +140.8% | Apr 12, 2024 |
| BMO Capital | Andrew Strelzik | $315 | $268.34 | +141.6% | Apr 12, 2024 |
| Deutsche Bank | Steve Powers | $264 | $268.34 | +102.5% | Apr 12, 2024 |
| Goldman Sachs | Bonnie Herzog | $300 | $268.34 | +130.1% | Apr 12, 2024 |
| Evercore ISI | Robert Ottenstein | $310 | $268.34 | +137.8% | Apr 12, 2024 |
| CFRA | Garrett Nelson | $270 | $267.4 | +107.1% | Apr 11, 2024 |
| Wells Fargo | Chris Carey | $295 | $266 | +126.3% | Apr 9, 2024 |
| RBC Capital | Nik Modi | $295 | $264.31 | +126.3% | Apr 5, 2024 |
| Deutsche Bank | Steve Powers | $262 | $268.14 | +101.0% | Apr 2, 2024 |
| Piper Sandler | Michael Lavery | $300 | $269.35 | +130.1% | Mar 21, 2024 |
| Roth Capital | William Kirk | $311 | $238.7 | +138.5% | Oct 6, 2023 |
| Goldman Sachs | Bonnie Herzog | $305 | $249.36 | +133.9% | Oct 5, 2023 |
| Wedbush | Gerald Pascarelli | $300 | $248.33 | +130.1% | Oct 3, 2023 |
| Morgan Stanley | Dara Mohsenian | $290 | $246.85 | +122.4% | Jun 30, 2023 |
| Evercore ISI | Analyst unavailable | $260 | $231.52 | +99.4% | Jan 31, 2023 |
| J.P. Morgan | Analyst unavailable | $250 | $214.23 | +91.7% | Jan 6, 2023 |
| Morgan Stanley | Analyst unavailable | $277 | $215 | +112.5% | Jan 6, 2023 |
| UBS | Analyst unavailable | $267 | $212.89 | +104.8% | Jan 6, 2023 |
| BMO Capital | Analyst unavailable | $265 | $208.68 | +103.3% | Jan 6, 2023 |
| Credit Suisse | Analyst unavailable | $250 | $208.68 | +91.7% | Jan 6, 2023 |
| Cowen & Co. | Analyst unavailable | $200 | $208.68 | +53.4% | Jan 6, 2023 |
| Wells Fargo | Analyst unavailable | $270 | $227.79 | +107.1% | Jan 3, 2023 |
| Deutsche Bank | Analyst unavailable | $245 | $232.77 | +87.9% | Dec 21, 2022 |
| Deutsche Bank | Analyst unavailable | $249 | $247.38 | +91.0% | Dec 6, 2022 |
| Barclays | Lauren Lieberman | $281 | $235.43 | +115.5% | Jul 5, 2022 |
| UBS | Analyst unavailable | $270 | $230.03 | +107.1% | Jun 21, 2022 |
| Jefferies | Kevin Grundy | $305 | $230.03 | +133.9% | Jun 14, 2022 |
| Goldman Sachs | Bonnie Herzog | $275 | $230.34 | +110.9% | Apr 5, 2022 |
| Morgan Stanley | Dara Mohsenian | $294 | $229.71 | +125.5% | Apr 4, 2022 |
| Jefferies | Kevin Grundy | $310 | $229.71 | +137.8% | Apr 4, 2022 |
| Barclays | Lauren Lieberman | $278 | $233.71 | +113.2% | Apr 1, 2022 |
| Wells Fargo | Christopher Carey | $275 | $225.85 | +110.9% | Mar 21, 2022 |
| Barclays | Lauren Lieberman | $277 | $248.64 | +112.5% | Jan 15, 2022 |
| Argus Research | John Staszak | $290 | $245.39 | +122.4% | Jan 7, 2022 |
| UBS | Sean King | $285 | $245.39 | +118.6% | Jan 7, 2022 |
| Citigroup | Wendy Nicholson | $265 | $245.39 | +103.3% | Jan 7, 2022 |
| Guggenheim | Laurent Grandet | $242 | $244.01 | +85.6% | Jan 6, 2022 |
| Cowen & Co. | Vivien Azer | $275 | $233.93 | +110.9% | Dec 8, 2021 |
| HSBC | Carlos Laboy | $262 | $217.68 | +101.0% | Oct 13, 2021 |
| Bernstein | Trevor Stirling | $305 | $234.1 | +133.9% | May 24, 2021 |
| Wolfe Research | Greg Badishkanian | $265 | $223.32 | +103.3% | Apr 12, 2021 |
Track every rating change on STZ the moment it posts. Free to start.
Start freeMarket reaction
event-close to next-session closeFollow STZ with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
EPS of $3.43 beat consensus of $3.22 by 6.5%; revenue of $2.43B exceeded estimates by 1.9%. Beer gross margins reached 39%, helped by 30bps of fixed-cost overabsorption and 20bps of pricing/mix, partially offset by 30bps of FX headwinds. Operating margins declined 10bps as SG&A rose from Veracruz staffing and marketing spend increased for World Cup support. Management raised full-year marketing spend expectations, with marketing exceeding 10% of net sales in Q2 and Q3. Corona non-alcoholic reached #4 in its category with strong double-digit growth, identified as a white-space opportunity. Jack Edwards, former Diageo beer executive, was hired as new Head of Sales to close distribution and awareness gaps.
Guidance delta
FY27 guidance was maintained despite the Q1 beat. Management explicitly cited limited macro visibility — gas prices spiked over 50% during the quarter — and the dynamic consumer environment, particularly within Hispanic ZIP codes, as reasons not to raise the outlook after one strong quarter. Prior quarter analysis noted that FY27 beer margin guidance had been lowered to 37-38% due to Veracruz fixed-cost absorption and higher SG&A; that margin outlook was not revised this quarter.
Key takeaways
- Beat driven by beer strength: EPS $3.43 vs $3.22 est (+6.5%), revenue $2.43B vs $2.39B est (+1.9%).
- Guidance maintained — management cited macro uncertainty and gas-price-driven consumer volatility as reasons not to raise FY27 outlook after one beat.
- Marketing spend stepped up materially — over 10% of net sales in Q2/Q3, targeting World Cup, college football, and NFL.
- Corona non-alcoholic is a genuine white-space win — #4 in category with strong double-digit growth; management sees room to invest further.
- Veracruz brewery remains on track for mid-fiscal-year commissioning, but pre-launch staffing is pressuring SG&A until it goes live.
- Market reaction was negative — stock fell 1.45% on the event and drifted down an additional 4.75% subsequently, with volume 1.86x baseline.
Management priorities
- Accelerate marketing investment in Q2/Q3 around World Cup, college football, and NFL to drive brand saliency and consumer occasions.
- Commission the Veracruz brewery mid-fiscal year to unlock fixed-cost absorption and shift SG&A into COGS.
- Close distribution and awareness gaps for Modelo Especial and core brands through new sales leadership.
- Scale Corona non-alcoholic and explore additional white-space opportunities using test-and-learn capabilities.
- Maintain cost-savings discipline to support gross margins amid rising SG&A and marketing spend.
- Deploy differentiated playbooks for established brands (saliency and relevance) versus emerging brands (distribution and awareness building).
Sources
- Earnings call transcript and parsed analysis · 2026-07-02T00:05:35.673721+00:00
- FN2 earnings calendar · 2026-07-30T01:23:13.872335+00:00
- Polygon adjusted daily market bars · 2026-07-31T00:11:49.221454+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-31T00:11:49.218742+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.